JD BIOSCIENCE

JD Bioscience (JDB) possesses the core technology and experience to design small molecules for the treatment for a variety of diseases. With its ability and expertise, JBD is developing new drug candidates for metabolic-related diseases. JDB founders have many years of experience working for major companies. Currently, JBD is collaborating with over 14 different companies in Korea and abroad assisting them in their research. Because this technology can be applied to proteolysis targeting chimera (PROTAC) or antibody drug conjugate (ADC), JBD can target an ever expanding range of indications, making it have technology with tremendous market potential.